The evolution of aldosterone antagonists.
Mol Cell Endocrinol
; 217(1-2): 27-31, 2004 Mar 31.
Article
em En
| MEDLINE
| ID: mdl-15134797
ABSTRACT
Since the isolation and purification of aldosterone from adrenal extracts 50 years ago (Experientia 9 (1953) 33), scientists have learned a great deal about how and where aldosterone acts, the factors that control its release, what is its role in the pathophysiology of cardiovascular disease, how to make and study aldosterone antagonists, and for what medical purposes these agents are useful. In this paper, we will discuss the evolution of aldosterone antagonists from the relatively nonselective spironolactone (Aldactone), to the highly selective eplerenone (Inspra). Eplerenone represents a molecule with improved steroid receptor selectivity and pharmacokinetic properties in man compared to spironolactone. Recent clinical results have demonstrated that these improvements translate into tolerability and efficacy in patients with cardiovascular disease.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Espironolactona
/
Antagonistas de Receptores de Mineralocorticoides
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Mol Cell Endocrinol
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Estados Unidos